Literature DB >> 17554504

Immune plasticity of bone marrow-derived mesenchymal stromal cells.

J Stagg1, J Galipeau.   

Abstract

Isolated from simple bone marrow aspirates, mesenchymal stromal cells (MSCs) can be easily expanded ex vivo and differentiated into various cell lineages. Because they are present in humans of all ages, are harvested in the absence of prior mobilization and preserve their plasticity following gene modification, MSCs are particularly attractive for cell-based medicine. One of the most fascinating properties of ex vivo expanded MSCs is their ability to suppress ongoing immune responses, both in vitro and in vivo. Although not fully understood, the immunosuppressive properties of MSCs have been reported to affect the function of a broad range of immune cells, including T cells, antigen-presenting cells, natural killer cells and B cells. Whereas successful harnessing of these immunosuppressive properties might one day open the door to the development of new cell-based strategies for the control of graft-versus-host and other autoimmune diseases, recent studies suggest that the immune-modulating properties of MSCs are far more complex than first thought. Reminiscent of the dichotomy of function of dendritic cells (DCs), which can act as potent activators or potent suppressors of immune responses, new studies including our own work has shown that MSCs in fact possess the dual ability to suppress or activate immune responses. In this review, we summarize the different biological properties of MSCs and discuss the current literature on the complex mechanism of immune modulation mediated by ex vivo expanded MSCs.

Entities:  

Mesh:

Year:  2007        PMID: 17554504     DOI: 10.1007/978-3-540-68976-8_3

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  22 in total

1.  Human embryonic stem cell-derived mesenchymal stromal cells.

Authors:  Peiman Hematti
Journal:  Transfusion       Date:  2011-11       Impact factor: 3.157

Review 2.  Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms.

Authors:  Darwin J Prockop
Journal:  Mol Ther       Date:  2009-03-31       Impact factor: 11.454

3.  Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome.

Authors:  Philippe M Campeau; Moutih Rafei; Marie-Noëlle Boivin; Ying Sun; Gregory A Grabowski; Jacques Galipeau
Journal:  Blood       Date:  2009-07-08       Impact factor: 22.113

4.  Isolation of therapeutically functional mouse bone marrow mesenchymal stem cells within 3 h by an effective single-step plastic-adherent method.

Authors:  F S-H Hsiao; C-C Cheng; S-Y Peng; H-Y Huang; W-S Lian; M-L Jan; Y-T Fang; E C-H Cheng; K-H Lee; W T-K Cheng; S-P Lin; S-C Wu
Journal:  Cell Prolif       Date:  2010-06       Impact factor: 6.831

5.  Advances in bone marrow-derived cell therapy: CD31-expressing cells as next generation cardiovascular cell therapy.

Authors:  Sung-Whan Kim; Hyongbum Kim; Young-sup Yoon
Journal:  Regen Med       Date:  2011-05       Impact factor: 3.806

6.  Induced pluripotent stem cells have similar immunogenic and more potent immunomodulatory properties compared with bone marrow-derived stromal cells in vitro.

Authors:  Lauren V Schnabel; Christian M Abratte; John C Schimenti; M Julia Bevilaqua Felippe; Jennifer M Cassano; Teresa L Southard; Jessica A Cross; Lisa A Fortier
Journal:  Regen Med       Date:  2014-04-28       Impact factor: 3.806

7.  Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients.

Authors:  Philippe M Campeau; Moutih Rafei; Moïra François; Elena Birman; Kathy-Ann Forner; Jacques Galipeau
Journal:  Mol Ther       Date:  2008-12-16       Impact factor: 11.454

8.  Autologous bone marrow stromal cells genetically engineered to secrete an igf-I receptor decoy prevent the growth of liver metastases.

Authors:  Ni Wang; Lucia Fallavollita; Long Nguyen; Julia Burnier; Moutih Rafei; Jacques Galipeau; Shoshana Yakar; Pnina Brodt
Journal:  Mol Ther       Date:  2009-04-14       Impact factor: 11.454

Review 9.  Role of mesenchymal stromal cells in solid organ transplantation.

Authors:  Peiman Hematti
Journal:  Transplant Rev (Orlando)       Date:  2008-07-24       Impact factor: 3.943

10.  Allogeneic non-adherent bone marrow cells facilitate hematopoietic recovery but do not lead to allogeneic engraftment.

Authors:  Stephan Fricke; Manuela Ackermann; Alexandra Stolzing; Christoph Schimmelpfennig; Nadja Hilger; Jutta Jahns; Guido Hildebrandt; Frank Emmrich; Peter Ruschpler; Claudia Pösel; Manja Kamprad; Ulrich Sack
Journal:  PLoS One       Date:  2009-07-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.